U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Recurrent Platinum-Resistant Primary Peritoneal Carcinoma

MedGen UID:
1765602
•Concept ID:
C5418769
•
Neoplastic Process

Definition

The reemergence of platinum-resistant primary peritoneal carcinoma after a period of remission. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRecurrent Platinum-Resistant Primary Peritoneal Carcinoma

Professional guidelines

PubMed

Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients.
Zhang N, Zheng H, Gao Y, Shu T, Wang H
BMC Womens Health 2023 Apr 13;23(1):178. doi: 10.1186/s12905-023-02329-9. PMID: 37055754Free PMC Article
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A, Kalachand R, Busschots S, Doherty B, Kapros E, Lawlor D, Hall N, Stordal BK
Cochrane Database Syst Rev 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3. PMID: 35866378Free PMC Article
The current treatment of recurrent ovarian cancer.
Herzog TJ
Curr Oncol Rep 2006 Nov;8(6):448-54. doi: 10.1007/s11912-006-0074-9. PMID: 17040623

Recent clinical studies

Etiology

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ
Int J Gynecol Cancer 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. PMID: 38101816
A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer.
Holloway RW, Thaker P, Mendivil AA, Ahmad S, Al-Niaimi AN, Barter J, Beck T, Chambers SK, Coleman RL, Crafton SM, Crane E, Ramez E, Ghamande S, Graybill W, Herzog T, Indermaur MD, John VS, Landrum L, Lim PC, Lucci JA, McHale M, Monk BJ, Moore KN, Morris R, O'Malley DM, Reid TJ, Richardson D, Rose PG, Scalici JM, Silasi DA, Tewari K, Wang EW
Int J Gynecol Cancer 2023 Sep 4;33(9):1458-1463. doi: 10.1136/ijgc-2023-004812. PMID: 37666539
Bevacizumab in recurrent ovarian cancer.
Sait Bakir M, Birge O, Karadag C, Ilhan Y, Aykut Tuncer H, Sezgin Göksu S, Simsek T
J BUON 2021 Jul-Aug;26(4):1271-1278. PMID: 34564981
Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
Martin JY, Urban RR, Liao JB, Goff BA
J Gynecol Oncol 2016 Sep;27(5):e47. Epub 2016 May 10 doi: 10.3802/jgo.2016.27.e47. PMID: 27329195Free PMC Article
Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma.
Rose PG
Int J Gynecol Cancer 2005 May-Jun;15 Suppl 1:18-22. doi: 10.1111/j.1525-1438.2005.15357.x. PMID: 15839954

Diagnosis

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ
Int J Gynecol Cancer 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. PMID: 38101816
Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas.
Arias-Diaz AE, Ferreiro-Pantin M, Barbazan J, Perez-Beliz E, Ruiz-Bañobre J, Casas-Arozamena C, Muinelo-Romay L, Lopez-Lopez R, Vilar A, Curiel T, Abal M
Int J Mol Sci 2023 Aug 25;24(17) doi: 10.3390/ijms241713208. PMID: 37686015Free PMC Article
Bevacizumab in recurrent ovarian cancer.
Sait Bakir M, Birge O, Karadag C, Ilhan Y, Aykut Tuncer H, Sezgin Göksu S, Simsek T
J BUON 2021 Jul-Aug;26(4):1271-1278. PMID: 34564981
Bevacizumab: a review of its use in advanced cancer.
Keating GM
Drugs 2014 Oct;74(16):1891-1925. doi: 10.1007/s40265-014-0302-9. PMID: 25315029
Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma.
Rose PG
Int J Gynecol Cancer 2005 May-Jun;15 Suppl 1:18-22. doi: 10.1111/j.1525-1438.2005.15357.x. PMID: 15839954

Therapy

Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer.
Bogani G, Coleman RL, Vergote I, van Gorp T, Ray-Coquard I, Oaknin A, Matulonis U, O'Malley D, Raspagliesi F, Scambia G, Monk BJ
Int J Gynecol Cancer 2024 Apr 1;34(4):469-477. doi: 10.1136/ijgc-2023-004924. PMID: 38101816
Relacorilant + Nab-Paclitaxel in Patients With Recurrent, Platinum-Resistant Ovarian Cancer: A Three-Arm, Randomized, Controlled, Open-Label Phase II Study.
Colombo N, Van Gorp T, Matulonis UA, Oaknin A, Grisham RN, Fleming GF, Olawaiye AB, Nguyen DD, Greenstein AE, Custodio JM, Pashova HI, Tudor IC, Lorusso D
J Clin Oncol 2023 Oct 20;41(30):4779-4789. Epub 2023 Jun 26 doi: 10.1200/JCO.22.02624. PMID: 37364223Free PMC Article
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, Provencher D, Memarzadeh S, Method M, Wang J, Moore KN, O'Malley DM
Gynecol Oncol 2023 Mar;170:241-247. Epub 2023 Feb 1 doi: 10.1016/j.ygyno.2023.01.020. PMID: 36736157
Bevacizumab in recurrent ovarian cancer.
Sait Bakir M, Birge O, Karadag C, Ilhan Y, Aykut Tuncer H, Sezgin Göksu S, Simsek T
J BUON 2021 Jul-Aug;26(4):1271-1278. PMID: 34564981
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN
Gynecol Oncol 2020 May;157(2):379-385. Epub 2020 Feb 18 doi: 10.1016/j.ygyno.2020.01.037. PMID: 32081463

Prognosis

Ascites-Derived Organoids to Depict Platinum Resistance in Gynaecological Serous Carcinomas.
Arias-Diaz AE, Ferreiro-Pantin M, Barbazan J, Perez-Beliz E, Ruiz-Bañobre J, Casas-Arozamena C, Muinelo-Romay L, Lopez-Lopez R, Vilar A, Curiel T, Abal M
Int J Mol Sci 2023 Aug 25;24(17) doi: 10.3390/ijms241713208. PMID: 37686015Free PMC Article
Efficacy and Safety of Platinum Rechallenge in Patients With Platinum-resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Multicenter Retrospective Study.
Tatsuki S, Shoji T, Abe M, Tomabechi H, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Aida T, Baba T
Anticancer Res 2022 Sep;42(9):4603-4610. doi: 10.21873/anticanres.15964. PMID: 36039449
Bevacizumab in recurrent ovarian cancer.
Sait Bakir M, Birge O, Karadag C, Ilhan Y, Aykut Tuncer H, Sezgin Göksu S, Simsek T
J BUON 2021 Jul-Aug;26(4):1271-1278. PMID: 34564981
Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
Safra T, Berman T, Yachnin A, Bruchim I, Meirovitz M, Barak F, Atlas I, Levy T, Rosengarten OS
Int J Gynecol Cancer 2013 Mar;23(3):475-80. doi: 10.1097/IGC.0b013e3182866944. PMID: 23435437
Platinum resistance and impaired survival in patients with advanced primary peritoneal carcinoma: matched-case comparison with patients with epithelial ovarian carcinoma.
Eisenhauer EL, Sonoda Y, Levine DA, Abu-Rustum NR, Gemignani ML, Sabbatini PJ, Barakat RR, Chi DS
Am J Obstet Gynecol 2008 Feb;198(2):213.e1-7. doi: 10.1016/j.ajog.2007.07.003. PMID: 18226627

Clinical prediction guides

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, Provencher D, Memarzadeh S, Method M, Wang J, Moore KN, O'Malley DM
Gynecol Oncol 2023 Mar;170:241-247. Epub 2023 Feb 1 doi: 10.1016/j.ygyno.2023.01.020. PMID: 36736157
Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Backes FJ, Wei L, Chen M, Hill K, Dzwigalski K, Poi M, Phelps M, Salani R, Copeland LJ, Fowler JM, Cohn DE, Bixel K, Cosgrove C, Hays J, O'Malley D
Gynecol Oncol 2021 Sep;162(3):619-625. Epub 2021 Jul 14 doi: 10.1016/j.ygyno.2021.06.032. PMID: 34272090
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
O'Malley DM, Matulonis UA, Birrer MJ, Castro CM, Gilbert L, Vergote I, Martin LP, Mantia-Smaldone GM, Martin AG, Bratos R, Penson RT, Malek K, Moore KN
Gynecol Oncol 2020 May;157(2):379-385. Epub 2020 Feb 18 doi: 10.1016/j.ygyno.2020.01.037. PMID: 32081463
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Coleman RL, Handley KF, Burger R, Molin GZD, Stagg R, Sood AK, Moore KN
Gynecol Oncol 2020 May;157(2):386-391. Epub 2020 Feb 7 doi: 10.1016/j.ygyno.2020.01.042. PMID: 32037195
A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC, Lele S, Richard S, Secord AA, Leath CA 3rd, Brower SL, Tian C, Moore RG
Am J Obstet Gynecol 2014 Jul;211(1):68.e1-8. Epub 2014 Feb 12 doi: 10.1016/j.ajog.2014.02.009. PMID: 24530815

Recent systematic reviews

Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A, Kalachand R, Busschots S, Doherty B, Kapros E, Lawlor D, Hall N, Stordal BK
Cochrane Database Syst Rev 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3. PMID: 35866378Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...